Hedge fund cuts United Therapeutics position by 6% in Q1 2026 but maintains long-term holding amid IPF drug progress.
Renaissance Technologies reduced its stake in United Therapeutics Corporation (NASDAQ:UTHR) by over 6% in the first quarter of 2026, holding just under 1.8 million shares. The hedge fund has maintained a long-term position in the biotech firm since reopening it in late 2014, after initially exiting in 2012.
United Therapeutics is advancing Tyvaso, an inhaled treatment for Idiopathic Pulmonary Fibrosis (IPF), following strong Phase 3 trial results. The drug showed significant lung function improvements over 52 weeks, positioning it as a potential first-in-class therapy. The company plans FDA submissions for approval.
The stock remains a consistent holding despite the recent trim, reflecting confidence in its clinical pipeline and market potential.